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article under the CC BY-NC-ND licenseAbstract Objective: Recently, serum cystatin C (CysC) has been used as a novel marker of
renal function. However, there is a lack of data on CysC levels in patients with intestinal uri-
nary diversion (UD). Here we report CysC levels in such patients.
Methods: We prospectively observed 38 patients who were diagnosed with bladder cancer and
subsequently treated with radical cystectomy and UD at our institution in 2012 and 2013.
Serum creatinine (sCr) and CysC were obtained optionally at the same time at least 1 month
after radical cystectomy and UD.
Results: The median CysC and sCr concentrations were 1.12 mg/L (range 0.75e2.47 mg/L) and
0.99 mg/dL (range 0.61e2.22 mg/dL), respectively. The median estimated concentrations of
glomerular filtration rate (GFR) based on CysC (eGFRcys) and GFR based on creatinine (eGFR-
creat) were 61.08 mL/min/1.73 m2 (range 22.64e99.89 mL/min/1.73 m2) and 58.01 mL/min/
1.73 m2 (range 23.48e91.82 mL/min/1.73 m2), respectively. CysC had a significant correlation
with sCr (rZ 0.8607, p < 0.0001) and eGFRcreat (rZ 0.8993, p < 0.0001). eGFRcys also had
a significant correlation with eGFRcreat (r Z 0.8104, p < 0.0001).of Urology, Sapporo Medical University, School of Medicine, Sapporo, Japan.
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168 M. Matsuki et al.Figure 1 (A) Correlation between
creatinine; eGFRcreat, estimated gConclusion: The correlation between CysC and sCr was strong and the correlation coefficient
was equivalent to that in patients without UD. The results suggest that CysC is not affected
by UD and can be used as a marker of renal function similarly to sCr in patients with UD.
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(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Radical cystectomy and intestinal urinary diversion (UD)
such as ileal conduit and ilealneobladder substitution are
standard treatments for patients with localized muscle
invasive bladder cancer. Some patients can obtain long-
term survival postoperatively but deterioration of the renal
function should be considered as an important complication
in the late period [1].
Although inulin clearance is the gold standard for eval-
uation of renal function, the procedure is too complicated
for routine use in the clinical setting. Therefore, renal
function is generally evaluated by serum creatinine (sCr)
and the estimated glomerular filtration rate (eGFR) based
on sCr. Recently, serum cystatin C (CysC) has been used as a
novel marker of renal function [2]. CysC is not affected by
the amount of muscle or the diet, unlike sCr. In addition,
the calculation of eGFR using CysC provides better accuracy
than eGFR based on sCr alone [3].
In patients with UD, substances in the urine can be
absorbed by the ileal mucosa exposed to the urine [4],
which may affect their concentrations in the serum. To
date, there has been a lack of data on CysC levels in pa-
tients with UD. Here we report CysC levels in such patients.
This study was a prospective observational study of pa-
tients who were diagnosed with bladder cancer and sub-
sequently treated with radical cystectomy and UD at
Sapporo Medical University Hospital and its affiliated hos-
pitals between 2012 and 2013. The protocol was approved
by the institutional review board (acceptance number
23e132). sCr and CysC were obtained optionally at the
same time at least 1 month after radical cystectomy and
UD. eGFR based on sCr (eGFRcreat) was calculated as fol-
lows: eGFRcreat (mL/min/1.73 m2) Z 194  Cr1.094CysC and sCr. (B) Correlation be
lomerular filtration rate based age0.287 (in females:  0.739) [5]. eGFR based on CysC
(eGFRcys) was calculated as follows: eGFRcys (mL/min/
1.73 m2) Z (104  CysC1.019  0.996age)  8 (in females:
(104  CysC1.019  0.996age  0.929)  8) [6]. Spearman’s
rank correlation analysis was performed between sCr,
sCysC, and eGFRcreat as well as eGFRcys and eGFRcreat.
Totally, 38 patients consisting of 33 males and five fe-
males were enrolled in this study. Their median age was 71
years (range 50e84 years). Of them, 33 (86.8%) and five
(13.2%) had an ileal conduit and ilealneobladder, respec-
tively. The median CysC and median sCr concentrations
were 1.12 mg/L (range 0.75e2.47 mg/L) and 0.99 mg/dL
(range 0.61e2.22 mg/dL), respectively. The median eGFR-
cys and eGFRcreat levels were 61.08 mL/min/1.73 m2
(range 22.64e99.89 mL/min/1.73 m2) and 58.01 mL/min/
1.73 m2 (range 23.48e91.82 mL/min/1.73 m2), respec-
tively. CysC had a significant correlation with
sCr(r Z 0.8607, p < 0.0001) and eGFRcreat (r Z 0.8993,
p < 0.0001) (Fig. 1). eGFRcys also had a significant corre-
lation with eGFRcreat (r Z 0.8104, p < 0.0001) (Fig. 2).
To the best of our knowledge, this is the first report
measuring CysC in patients with UD. The correlation be-
tween CysC and sCr was strong and the correlation coeffi-
cient was equivalent to that in patients without UD [7]. The
results of this study suggest that CysC can be used as a
marker of renal function similarly to sCr and eGFRcreat in
patients with UD.
In patients with UD, substances in the urine can be
reabsorbed by the ileal mucosa exposed to the urine.
Rinnab et al. [4] reported that urinary creatinine and urea
were potentially reabsorbed into the ilealneobladder,
which could affect their concentrations in the serum,tween CysC and eGFRcreat. CysC, serum cystatin C; sCr, serum
on serum creatinine.
Figure 2 Correlation between eGFRcys and eGFRcreat.
eGFRcys, estimated glomerular filtration rate based on serum
cystatin C; eGFRcreat, estimated glomerular filtration rate
based on serum creatinine.
Serum CysC marker of renal function in patients with UD 169although the status was different among individuals and the
clinical significance was not determined. Cystatin C in the
urine can also potentially be absorbed in the ileal segment.
However, the urinary concentration of cystatin C in normal
subjects is low [8] because cystatin C is absorbed and
rapidly degraded by the proximal tubular cells after being
filtered in the glomeruli [9]. Therefore, the serum con-
centration may barely be affected even if urinary cystatin C
is absorbed by the ileal mucosa. Essentially, the relation-
ship between CysC and inulin clearance should be verified.
However, sCr has been used to assess renal function in
patients with UD [1] and the compatibility between CysC
and sCr may indicate the clinical usefulness of CysC.
Because CysC provides more accuracy in calculation of
eGFR, the KDIGO 2012 clinical practice guideline [10]
recommend the use of eGFR considering CysC. Therefore
we should assess renal function by using CysC to manage
chronic kidney disease in patients with UD.
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